Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.”In the company’s words, NCT01522417 on ClinicalTrials.gov
- Tested for
- Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
- Main trialPhase 2
- “The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.”In the company’s words, NCT01522417 on ClinicalTrials.gov
- Other names
- Aggrastat
Other drugs for Myocardial Infarction
- InclisiranNovartis · Phase 3
- MLC1501Moleac Pte Ltd. · Phase 2/3
- ZiltivekimabNovo Nordisk · Phase 3
- ClazakizumabCSL Behring · Phase 2/3
- PelacarsenNovartis · Phase 3
- PacibekitugNovartis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | Dec 2018 | Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026